Sanjay Shah, MD
Internal Medicine · The Villages, FLNPI 1215986211
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 49.5% of the total. Reporting peaked in 2023 at $1,184 and has fallen 96.5% since, to $41 in 2025.
Across 36 payments — averaging $55.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$992
- Vertos Medical, Inc.$149
- Astellas Pharma US Inc$135
- Idorsia Pharmaceuticals US Inc$125
- E.r. Squibb & Sons, L.L.C.$98
- Novo Nordisk$72
- plus $434 from 14 others
Across 134 payments — averaging $7886.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Seikagaku Corporation$657K
- Sanofi US Services Inc.$203K
- Lexicon Pharmaceuticals, Inc.$111K
- Chiesi USA, Inc.$76K
- Boehringer Ingelheim International GmbH$5K
- AstraZeneca$5K
What the payments were for
- Travel & lodging$99249%
- Food & beverage$91346%
- Education$1005%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $992 |
| Vertos Medical, Inc. | 1 | $149 |
| Astellas Pharma US Inc | 3 | $135 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Novo Nordisk | 3 | $72 |
| Novartis | 3 | $63 |
| Lilly USA, LLC | 3 | $56 |
| GSK | 3 | $47 |
| Johnson & Johnson | 3 | $46 |
| Boston Scientific | 1 | $41 |
| Melinta Therapeutics, LLC | 2 | $33 |
| Bayer | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENSITE PRECISION$983
- mild Device Kit$149
- QUVIVIQ$125
How this compares
$2,005 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 207 | $295,670 |
| EliquisApixaban | 182 | $233,786 |
| JanuviaSitagliptin Phosphate | 102 | $144,058 |
| XareltoRivaroxaban | 76 | $93,192 |
| FarxigaDapagliflozin Propanediol | 70 | $86,800 |
| OzempicSemaglutide | 46 | $72,316 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $49,125 |
| LinzessLinaclotide | 26 | $38,322 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $33,313 |
| EntrestoSacubitril/Valsartan | 23 | $29,251 |
| ProliaDenosumab | 14 | $23,929 |
| MyrbetriqMirabegron | 21 | $22,350 |
| Rosuvastatin Calcium | 1,122 | $16,766 |
| MounjaroTirzepatide | 12 | $16,725 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 57 | $16,550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $46 | $93,19276 claims |
| Novo NordiskOzempic, Levemir | $72 | $80,77463 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $47 | $65,55652 claims |
| NovartisEntresto | $63 | $29,25123 claims |
| AmgenProlia | $17 | $23,92914 claims |
| Astellas Pharma US IncMyrbetriq | $135 | $22,35021 claims |
| Lilly USA, LLCMounjaro | $56 | $16,72512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in The Villages
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.